Cloniprazepam

The topic of Cloniprazepam is of utmost importance today, as it has a significant impact on various areas of daily life. From its influence on the economy to its role in society, Cloniprazepam is a topic that does not go unnoticed. Throughout history, it has been the subject of debate and analysis, and its relevance remains valid today. In this article, we will explore the different facets of Cloniprazepam and its importance in today's world.

Cloniprazepam
Clinical data
Other names1-Cyclopropylmethylclonazepam, Kloniprazepam, 2-Chloro-7'-nitroprazepam
Drug classBenzodiazepines
Legal status
Legal status
Identifiers
  • 5-(2-Chlorophenyl)-1-(cyclopropylmethyl)-7-nitro-1,3-dihydro-2H-benzodiazepin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H16ClN3O3
Molar mass369.81 g·mol−1
3D model (JSmol)
  • O=C1N(CC2CC2)C3=CC=C(()=O)C=C3C(C4=CC=CC=C4Cl)=NC1
  • InChI=1S/C19H16ClN3O3/c20-16-4-2-1-3-14(16)19-15-9-13(23(25)26)7-8-17(15)22(11-12-5-6-12)18(24)10-21-19/h1-4,7-9,12H,5-6,10-11H2
  • Key:CCSYKGYLSFXNTA-UHFFFAOYSA-N
Metabolic pathway of cloniprazepam

Cloniprazepam is a benzodiazepine derivative and a prodrug of clonazepam, 7-aminoclonazepam, and other metabolites.

Some of the minor metabolites include 3-hydroxyclonazepam and 6-hydroxyclonazepam, 3-hydroxycloniprazepam and ketocloniprazepam with ketone group formed where 3-hydroxy group was.

It is a designer drug and an NPS (short for "new psychoactive substance"). At the end of 2017, cloniprazepam was an uncontrolled substance in most of the countries.

See also

References

  1. ^ a b c Moosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). "Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam". Journal of Mass Spectrometry. 51 (11): 1080–1089. Bibcode:2016JMSp...51.1080M. doi:10.1002/jms.3840. PMID 27535017.
  2. ^ Mortelé O, Vervliet P, Gys C, Degreef M, Cuykx M, Maudens K, et al. (May 2018). "In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry". Journal of Pharmaceutical and Biomedical Analysis. 153: 158–167. doi:10.1016/j.jpba.2018.02.032. hdl:10067/1496330151162165141. PMID 29494888. S2CID 3946404.

External links